Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

CD93 CAR T cells eliminate AML in preclinical models without targeting hematopoietic progenitor cells, and a NOT-gated CAR engineering strategy mitigates on-target, off-tumor toxicity...

Mashup Score:10

VJHemOnc

Post-ASH 2022 Highlights - 19 hours

Mashup Score:10

Apply to register for the Post-ASH 2022 iwAL Virtual Workshop, featuring key abstracts in hematological malignancies presented at ASH...

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson...

Abstract. Isocitrate dehydrogenase 1 and 2 (IDH) are mutated in multiple cancers and drive production of (R)-2-hydroxyglutarate (2HG). We identified a lipid synthesis enzyme...

Closing out their discussion, Drs Hetty Carraway and Eytan M. Stein highlight an ongoing clinical trial investigating a triplet therapy for...

A conditioning regimen consisting of of Iomab-B prior to a bone marrow transplant met the phase 3 SIERRA trial’s primary end point of durable...

  • 1596187900638535681 Profile photo of Madelyn

    A conditioning regimen consisting of of Iomab-B prior to a bone marrow transplant met the phase 3 SIERRA trial’s primary end point of durable complete remission vs conventional care in elderly patients with relapsed or refractory #AML. https://t.co/lHdLScUeXj - view on twitter

Mashup Score:2

lww.com

Wolters Kluwer Health - 2 days

Mashup Score:2

JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers:...

Mashup Score:1

lww.com

Wolters Kluwer Health - 1 week

Mashup Score:1

JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers:...

A conditioning regimen consisting of of Iomab-B prior to a bone marrow transplant met the phase 3 SIERRA trial’s primary end point of durable...

  • 1593982984046125058 Profile photo of Madelyn

    A conditioning regimen consisting of of Iomab-B prior to a bone marrow transplant met the phase 3 SIERRA trial’s primary end point of durable complete remission vs conventional care in elderly patients with R/R acute myeloid leukemia. #AML https://t.co/cerm0m9NgL - view on twitter